百利天恒iza-bren用于治疗复发性或转移性食管鳞癌被纳入优先审评程序

Core Viewpoint - Baili Tianheng (688506) announced that its self-developed, first-in-class EGFR×HER3 dual antibody ADC (injectable iza-bren) has been included in the priority review list by the National Medical Products Administration (NMPA) [1] Group 1 - Iza-bren is the world's first EGFR×HER3 dual antibody ADC to be included in the priority review list [1] - As of now, iza-bren has been recognized as a breakthrough therapy for recurrent or metastatic esophageal squamous cell carcinoma that has failed previous PD-1/PD-L1 monoclonal antibody combined with platinum-based chemotherapy [1] - The interim analysis for the Phase III clinical trial of iza-bren has achieved dual primary endpoints of progression-free survival (PFS) and overall survival (OS) [1] Group 2 - Iza-bren has two indications that have been included in the priority review list by the NMPA [1]